在没有受损的老年人中,与和粉样蛋白相关的日常功能变化,有或没有粉样蛋白升高
Mark A Dubbelman1,2, Andy Liu3, Michael C Donohue3
1Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School.
Neurology
|May 29, 2025
概括
在临床前的阿尔茨海默病中,较高的水平,而不是单独的粉样蛋白,预测日常功能下降的速度更快. 监测tau积累对于早期干预策略至关重要.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 神经退行症的生物标志物
背景情况:
- 阿尔茨海默病 (AD) 的特点是日常功能逐渐下降,可能从临床前阶段开始.
- 早期检测功能变化对于及时干预阿尔茨海默病至关重要.
- 在认知不受损的个体中,调查日常功能和关键的AD病理 (粉样和) 之间的关系至关重要.
研究的目的:
- 检查日常功能中的变化如何与粉样蛋白和蛋白生物标志物的变化相关.
- 评估粉样蛋白和蛋白水平对临床前阿尔茨海默病患者功能衰退的预测值.
- 识别疾病过程中早期出现的特定功能困难.
主要方法:
- 对认知不受损的老年人进行前性研究,包括临床试验的参与者和查失败的个人.
- 重复的定子发射断层扫描 (PET) 扫描是在参与者的子集上进行的.
- 用通用最小平方模型分析了日常功能变化 (通过ADCS ADL-PI测量) 和粉样蛋白/粉样蛋白PET成像结果之间的关系.
主要成果:
- 在整个研究队列中观察到日常运作的边际下降.
- 高粉样蛋白与较高的新皮层和中部形水平相结合,预测了日常功能最显著的下降.
- 的增加与功能下降有中等的相关性,而单独的粉胺不能预测功能变化.
- 与复杂活动和购物相关任务的困难是最常见的功能性挑战.
结论:
- 较高的水平与在粉样蛋白水平升高的情况下,日常功能加速下降有关.
- 的积累是临床前阿尔茨海默病患者功能衰退的关键驱动因素.
- 对日常运作的敏感测量是临床实践和临床前AD阶段的试验中宝贵的工具.
相关概念视频
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Cognitive Development During Adulthood
312
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
312
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182


